POM-V Prescription Required

Zeleris

Active ingredients: Florfenicol, Meloxicam

Form

Injection

Species

Cattle

Manufacturer

Ceva Sante Animale

VMD MA No.

EU/2/17/210/001–003

What it's used for

AN: 00849/2023Page 2 of 8

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Florfenicol + Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Zeleris — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

AN: 00849/2023Page 2 of 8

40 mg of florfenicol per kg bodyweight and 2.2 mg of flunixin per kg bodyweight
(equivalent to 2 mL of product per 15 kg body weight) to be administered by a single
subcutaneous injection.
The dose volume given at any one injection site should not exceed 10mL.
The cap may be safely punctured up to 25 times. When treating groups of animals in
one run, use a draw-off needle that has been placed in the vial stopper to avoid
excess broaching of the stopper. The draw-off needle should be removed after
treatment.
It is recommended to treat animals in the early stages of the disease and to evaluate
the response to treatment 48 hours after injection. The anti-inflammatory component
of this veterinary product, flunixin, may mask resistance to florfenicol in the first 24
hours after injection. If clinical signs of respiratory disease persist or increase, or if
relapse occurs, treatment should be changed, using another antibiotic, and continued
until clinical signs have resolved.
The injection should only be given in the neck.
Swab septum before removing each dose. Use a dry sterile needle and syringe.
To ensure a correct dosage body weight should be determined as accurately as
possible to avoid underdosing.

Do not use in adult bulls intended for breeding purposes.
Do not use in animals suffering from hepatic and renal diseases.
Do not use if there is a risk of gastrointestinal bleeding or in cases where there is
evidence of altered hemostasis.
Do not use in animals suffering from cardiac diseases.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.

Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Anaphylactic-type reaction
Undetermined
frequency
Application site swelling
1
Those reactions might be fatal.
Subcutaneous administration of the product may result in application site swelling
that become palpable 2-3 days after injection. The duration of the application site
swelling ranged from 15-36 days post-injection. Grossly, this is associated with
minimal to mild irritation of the subcutis. Extension into the underlying muscle was
noted in only a few instances. By 56 days post-dosing, no gross lesions were
observed that would require any trim-out at slaughter.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also section 16 of the
package leaflet for respective contact details.

None.

Special precautions for safe use in the target species:
Use of the product should be based on susceptibility testing of the bacteria isolated
from the animal. If this is not possible, therapy should be based on local (regional,
farm level) epidemiological information about susceptibility of the target bacteria.
Official and local antimicrobial policies should be taken into account when the
product is used.
Use of the product deviating from the instructions given in the SPC may increase the
prevalence of bacteria resistant to florfenicol.
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential
risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic
drugs should be avoided.
Repeated daily dosing has been associated with abomasal erosions in the pre-
ruminant calf. The product should be used with caution in this age group.
The safety of the product has not been tested in calves of 3 weeks of age or less.
Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to
enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure
that they are not made available to wild fauna.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This product may cause adverse effects. Care should be taken to avoid accidental
self-injection.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have
shown evidence of foetotoxic effects. Women of childbearing age, pregnant women
or women suspected of being pregnant should use the veterinary medicinal product
with serious caution to avoid accidental self-injection.
This veterinary medicinal product may cause hypersensitivity reactions (allergy).
People with known hypersensitivity to propylene glycol and polyethylene glycols
AN: 00849/2023Page 3 of 8
should avoid contact with the veterinary medicinal product. If you develop symptoms
following exposure, such as skin rash, swelling of the face, lips or eyes or difficulty
with breathing, you should seek medical advice immediately and show the package
leaflet or the label to the physician.
Wash hands after use.

Concurrent use of other active substances that have a high degree of protein binding
may compete with flunixin for binding and thus lead to toxic effects. Pre-treatment
with other anti-inflammatory substances may result in additional or increased adverse
effects and accordingly a treatment-free period with such drugs should be observed
for at least 24 hours before the commencement of
treatment. The treatment-free period, however, should take into account the
pharmacokinetic properties of the products used previously.
The product must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Gastrointestinal tract ulceration may be exacerbated by
corticosteroids in animals given NSAIDs.
AN: 00849/2023Page 4 of 8

Do not store above 25 C.
Store in the original package.

Meat and offal: 46 days.
Milk: Not authorised for use in animals producing milk for human consumption. Do
not use during lactation or drying off periods. Do not use in pregnant animals which
are intended to produce milk for human consumption within 2 months of expected
parturition.
AN: 00849/2023Page 5 of 8

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.